Clicky

Bavarian Nordic A/S(BVNKF)

Description: Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark.


Keywords: Biotechnology Cancer Clinical Medicine Life Sciences Drugs Infectious Diseases Prostate Cancer Vaccines Department Of Defense HPV Ebola Myer Papillomavirus And Cancer National Cancer Institute Metastatic Cancer Ebola Vaccine Bavarian Nordic Biomedical Advanced Research And Development Authority Treatment Of Metastatic Cancer Tva Prostvac Company Markets Non Replicating Smallpox Cv301 Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer Prevention Of Respiratory Treatment Multiple Cancers Treatment Of Life Threatening Infectious Diseases Us Department Of Defense

Home Page: www.bavarian-nordic.com

Philip Heymans Alle 3
Hellerup, 2900
Denmark
Phone: 45 33 26 83 83


Officers

Name Title
Dr. Paul John Chaplin MSc, Ph.D. CEO & Pres
Mr. Henrik Juuel M.Sc. CFO & Exec. VP
Mr. Russell Thirsk Exec. VP & COO
Mr. Rolf Sass Sørensen VP of Investor Relations & Communications
Ms. Anu Helena Kerns Exec. VP & Chief People Officer
Mr. Jean-Christophe May Exec. VP & Chief Commercial Officer
Dr. Laurence De Moerlooze Exec. VP & Chief Medical Officer

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 4.6382
Trailing PE: 0
Price-to-Book MRQ: 2.2109
Price-to-Sales TTM: 0.9158
IPO Date:
Fiscal Year End: December
Full Time Employees: 917
Back to stocks